The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis

被引：0
|
作者：
Seong-Jang Kim
Kyoungjune Pak
Phillip J. Koo
Jennifer J. Kwak
Samuel Chang
机构：
[1] Pusan National University Hospital,Department of Nuclear Medicine and Biomedical Research Institute
[2] University of Colorado School of Medicine,Department of Radiology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2015年 / 42卷
关键词：
Neuroendocrine tumour; Lutetium; Radionuclide therapy; Peptide receptor therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1964 / 1970
页数：6
相关论文
共 50 条
  • [21] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
    Geenen, Lorain
    Nonnekens, Julie
    Konijnenberg, Mark
    Baatout, Sarah
    De Jong, Marion
    Aerts, An
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 102 : 1 - 11
  • [22] Peptide receptor radionuclide therapy of neuroendocrine tumours with 177Lu-octreotate: first experience in a French Canadian centre
    Del Prete, M.
    Buteau, F. A.
    Beauregard, J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S725 - S725
  • [23] Dose response of pancreatic neuroendocrine tumours treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE
    Ilan, E.
    Sandstrom, M.
    Garske-Roman, U.
    Sundin, A.
    Wassberg, C.
    Lubberink, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S223 - S224
  • [24] A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
    Germo Gericke
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 2666 - 2667
  • [25] EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
    Clemens Kratochwil
    Wolfgang Peter Fendler
    Matthias Eiber
    Richard Baum
    Murat Fani Bozkurt
    Johannes Czernin
    Roberto C. Delgado Bolton
    Samer Ezziddin
    Flavio Forrer
    Rodney J. Hicks
    Thomas A. Hope
    Levant Kabasakal
    Mark Konijnenberg
    Klaus Kopka
    Michael Lassmann
    Felix M. Mottaghy
    Wim Oyen
    Kambiz Rahbar
    Heiko Schöder
    Irene Virgolini
    Hans-Jürgen Wester
    Lisa Bodei
    Stefano Fanti
    Uwe Haberkorn
    Ken Herrmann
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 2536 - 2544
  • [26] Peptide receptor radionuclide therapy with 177Lu-octreotate in foregut carcinoid tumours
    Van Essen, M.
    Krenning, E. P.
    Bakker, W. H.
    Kooij, P. P.
    Kwekkeboom, D. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S215 - S215
  • [27] 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (12) : 1195 - 1203
  • [28] Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
    Kim K.
    Kim S.-J.
    Nuclear Medicine and Molecular Imaging, 2018, 52 (3) : 208 - 215
  • [29] Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumors of the small intestine
    Sabet, A.
    Dautzenberg, K.
    Haslerud, T.
    Aouf, A.
    Sabet, A.
    Simon, B.
    Mayer, K.
    Biersack, H.
    Ezziddin, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S211 - S211
  • [30] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Becx, Morticia N.
    Minczeles, Noemie S.
    Brabander, Tessa
    de Herder, Wouter W.
    Nonnekens, Julie
    Hofland, Johannes
    CANCERS, 2022, 14 (23)
12345